Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

New England Journal of Medicine - Tập 372 Số 21 - Trang 2018-2028 - 2015
Edward B. Garon1, Naiyer A. Rizvi2, Rina Hui3, Natasha B. Leighl4, Ani Sarkis Balmanoukian5, Joseph P. Eder6, Amita Patnaik7, Charu Aggarwal8, Matthew A. Gubens9, Leora Horn10, Enric Carcereny11, Myung‐Ju Ahn12, Enriqueta Felip13, Jong-Seok Lee14, Matthew D. Hellmann15, Omid Hamid5, Jonathan W. Goldman1, Jean‐Charles Soria16, Marisa Dolled‐Filhart17, Ruth Z. Rutledge17, Jin Zhang17, Jared Lunceford17, Reshma Rangwala17, Gregory M. Lubiniecki17, Charlotte Roach18, Kenneth Emancipator17, Leena Gandhi19
1David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica
2Columbia University
3Westmead Hospital, University of Sydney, Westmead, NSW, Australia
4Princess Margaret Cancer Centre, Toronto
5Angeles Clinic and Research Institute, Los Angeles
6Yale University, New Haven, CT
7South Texas Accelerated Research Therapeutics, San Antonio
8Abramson Cancer Center of the University of Pennsylvania, Philadelphia
9University of California – San Francisco, San Francisco
10Vanderbilt–Ingram Cancer Center, Nashville
11Catalan Institute of Oncology Badalona, Badalona
12Samsung medical center
13Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona
14Seoul National University
15Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
16Institut Gustave Roussy and Université Paris-Sud, Villejuif, France
17Merck, Kenilworth, NJ
18Dako, Carpinteria
19Dana Farber Cancer Institute, Boston

Tóm tắt

Từ khóa


Tài liệu tham khảo

Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012, version 1.0. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer, 2013 (http://globocan.iarc.fr).

10.3322/caac.21254

10.3747/co.19.1114

10.1200/JCO.2012.43.7459

10.1016/j.cell.2011.02.013

10.1038/nri727

10.1146/annurev.immunol.26.021607.090331

10.1084/jem.192.7.1027

10.1038/nm0902-1039c

10.1126/science.1203486

10.1146/annurev-immunol-031210-101324

10.1038/nrc3239

10.1097/PPO.0000000000000063

10.1056/NEJMoa1200694

10.1056/NEJMoa1200690

10.1038/nature14011

10.1038/nature13954

Lindauer A, Valiathan C, Mehta K, et al. Translational pharmacokinetic/pharmacodynamic model of tumor growth inhibition by the new anti-PD1 monoclonal antibody MK-3475. Presented at the 23rd Meeting of the Population Approach Group in Europe, Alicante, Spain, June 10–13, 2014.

Ahamadi M, Prohn M, Rossenu S, et al. Population pharmacokinetics of MK-3475, a human anti-PD-1 monoclonal antibody in patients with progressive locally advanced or metastatic carcinoma, melanoma, and non-small cell lung cancer. Presented at the 23rd Meeting of the Population Approach Group in Europe, Alicante, Spain, June 10–13, 2014.

10.1158/1078-0432.CCR-09-1624

10.1016/j.ejca.2008.10.026

10.1158/0008-5472.CAN-13-3694

10.1200/JCO.2004.08.163

10.1056/NEJMoa1305133

10.1016/S0140-6736(14)60958-2

Robert C, 2014, Ann Oncol, 25, LBA34

10.1200/JCO.2014.57.4673

10.1093/annonc/mdu101

10.1016/j.ejso.2015.01.020

10.1038/nature12477

10.1038/bjc.2014.555

10.1056/NEJMoa0810699

10.1056/NEJMoa1214886

10.1056/NEJMoa1408440

10.1038/nm1517

10.1158/2159-8290.CD-13-0458

10.1056/NEJMoa1406498

10.1182/blood-2006-10-051482

10.1182/blood-2009-12-255125

10.1126/scitranslmed.3003689

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 372 Số 21

2018-2028

Thông tin tác giả